In CHF with reduced ejection fraction (HFrEF), ACE-Inhibitors reduced mortality by 8–16%, while β-blockers reduced mortality by 31–34%, according to the MERIT-HF, CIBIC II and COPERNICUS trials [46]. This evidence concerns the gene ACE and congestive heart failure.